泓博医药(301230.SZ)：现阶段公司DiOrion平台药物研发服务的直接收入占整体营业收入的比重较小

Core Viewpoint - Hongbo Pharmaceutical (301230.SZ) announced that the direct revenue from its DiOrion platform drug development services currently constitutes a small proportion of the company's overall operating income, and does not significantly impact the company's overall business performance [1] Group 1 - The company reported unusual stock trading fluctuations and severe abnormal trading activity [1] - An internal review found no undisclosed significant information in public media that could have substantially affected the company's stock price [1]